NMD Phar­ma se­cures €75M from in­sid­ers for three PhII tri­als in neu­ro­mus­cu­lar dis­or­ders

Dan­ish biotech NMD Phar­ma, named for its fo­cus on neu­ro­mus­cu­lar dis­or­ders, has tacked on €75 mil­lion ($81 mil­lion) to bankroll three Phase II stud­ies of its main drug can­di­date.

The fund­ing will sup­port Phase II tri­als of its CIC-1 mol­e­cule in­hibitor NMD670 in pa­tients with spinal mus­cu­lar at­ro­phy (SMA), myas­the­nia gravis and Char­cot-Marie-Tooth dis­ease, NMD said Wednes­day morn­ing.

It al­so gives NMD an­oth­er three years of run­way, CEO Thomas Holm Ped­er­sen told End­points News. The SMA tri­al will be the first one to read out da­ta, some­time in 2025. The SMA study has al­ready be­gun, and the oth­er two tri­als will start next year, he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER